These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38823902)

  • 1. Overview of the current procedures in synthesis of heparin saccharides.
    Zhao S; Zhang T; Kan Y; Li H; Li JP
    Carbohydr Polym; 2024 Sep; 339():122220. PubMed ID: 38823902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient synthesis of Idraparinux, the anticoagulant pentasaccharide.
    Chen C; Yu B
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3875-9. PubMed ID: 19386495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoenzymatic synthesis of the next generation of ultralow MW heparin therapeutics.
    Masuko S; Linhardt RJ
    Future Med Chem; 2012 Mar; 4(3):289-96. PubMed ID: 22393937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The synthesis of 1,2-cis-amino containing oligosaccharides toward biological investigation.
    Manabe S
    Methods Enzymol; 2010; 478():413-35. PubMed ID: 20816492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent chemical and enzymatic approaches to the synthesis of glycosaminoglycan oligosaccharides.
    Karst NA; Linhardt RJ
    Curr Med Chem; 2003 Oct; 10(19):1993-2031. PubMed ID: 12871100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De novo synthesis of a narrow size distribution low-molecular-weight heparin.
    Chandarajoti K; Xu Y; Sparkenbaugh E; Key NS; Pawlinski R; Liu J
    Glycobiology; 2014 May; 24(5):476-86. PubMed ID: 24626379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Efficient Modular One-Pot Synthesis of Heparin-Based Anticoagulant Idraparinux.
    Dey S; Lo HJ; Wong CH
    J Am Chem Soc; 2019 Jul; 141(26):10309-10314. PubMed ID: 31244187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of heparin oligosaccharides and their interaction with eosinophil-derived neurotoxin.
    Hung SC; Lu XA; Lee JC; Chang MD; Fang SL; Fan TC; Zulueta MM; Zhong YQ
    Org Biomol Chem; 2012 Jan; 10(4):760-72. PubMed ID: 22143347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facile chemoenzymatic synthesis of unmodified anticoagulant ultra-low molecular weight heparin.
    Zhang G; Yang K; Wang L; Cheng Y; Liu C
    Org Biomol Chem; 2022 Nov; 20(42):8323-8330. PubMed ID: 36239281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Modular Synthetic Approach to Isosteric Sulfonic Acid Analogues of the Anticoagulant Pentasaccharide Idraparinux.
    Mező E; Eszenyi D; Varga E; Herczeg M; Borbás A
    Molecules; 2016 Nov; 21(11):. PubMed ID: 27845725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide.
    Walenga JM; Jeske WP; Bara L; Samama MM; Fareed J
    Thromb Res; 1997 Apr; 86(1):1-36. PubMed ID: 9172284
    [No Abstract]   [Full Text] [Related]  

  • 12. Total synthesis of anticoagulant pentasaccharide fondaparinux.
    Li T; Ye H; Cao X; Wang J; Liu Y; Zhou L; Liu Q; Wang W; Shen J; Zhao W; Wang P
    ChemMedChem; 2014 May; 9(5):1071-80. PubMed ID: 24729477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.
    Petitou M; Nancy-Portebois V; Dubreucq G; Motte V; Meuleman D; de Kort M; van Boeckel CA; Vogel GM; Wisse JA
    Thromb Haemost; 2009 Nov; 102(5):804-10. PubMed ID: 19888512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of the heparin-based anticoagulant drug fondaparinux.
    Chang CH; Lico LS; Huang TY; Lin SY; Chang CL; Arco SD; Hung SC
    Angew Chem Int Ed Engl; 2014 Sep; 53(37):9876-9. PubMed ID: 25044485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical synthesis and pharmacological properties of heparin pentasaccharide analogues.
    Zhou Z; Zhang L; Wu X; Luo L; Wu J; Xu D; Wu M
    Eur J Med Chem; 2022 Apr; 234():114256. PubMed ID: 35279609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A latent reactive handle for functionalising heparin-like and LMWH deca- and dodecasaccharides.
    Miller GJ; Broberg KR; Rudd C; Helliwell MR; Jayson GC; Gardiner JM
    Org Biomol Chem; 2015 Dec; 13(46):11208-19. PubMed ID: 26381107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoenzymatic synthesis of heparin oligosaccharides with both anti-factor Xa and anti-factor IIa activities.
    Xu Y; Pempe EH; Liu J
    J Biol Chem; 2012 Aug; 287(34):29054-61. PubMed ID: 22773834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic heparin and heparan sulfate oligosaccharides and their protein interactions.
    Zulueta MM; Lin SY; Hu YP; Hung SC
    Curr Opin Chem Biol; 2013 Dec; 17(6):1023-9. PubMed ID: 24182748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational design of anticoagulant drugs using oligosaccharide chemistry.
    El Hadri A; Petitou M
    Chimia (Aarau); 2011; 65(1-2):14-7. PubMed ID: 21469438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic oligosaccharides as active pharmaceutical ingredients: lessons learned from the full synthesis of one heparin derivative on a large scale.
    Driguez PA; Potier P; Trouilleux P
    Nat Prod Rep; 2014 Aug; 31(8):980-9. PubMed ID: 24705477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.